Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250666 | 0.82 | SSTR2 (0.38) | KCNH2FFAR4 | |
| SCHEMBL241457 | 0.81 | SSTR2 (0.34) | FFAR4OPRK1 | |
| SCHEMBL27358364 | 0.77 | FFAR4 (0.35) | CYP2D6KCNH2HRH3FFAR4 | |
| SCHEMBL16249187 | 0.76 | ALDH1A1 (0.36) | — | |
| SCHEMBL14924079 | 0.75 | MAPT (0.42) | CYP2D6 | |
| SCHEMBL16249188 | 0.75 | SLC18A3 (0.43) | KCNH2HRH3 | |
| SCHEMBL16788907 | 0.73 | SLC6A2 (0.37) | FFAR4 | |
| SCHEMBL20883672 | 0.73 | ALDH1A1 (0.46) | — | |
| SCHEMBL21654083 | 0.73 | GAA (0.41) | — | |
| SCHEMBL25964449 | 0.72 | HSD11B1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (IL) | 2014-12-11 | — | — | US | disclosed |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP2D6 3294/4885KCNH2 4567/4885HRH3 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.